Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Regina Clementi"'
Autor:
Bronwyn A. Kingwell, Danielle Duffy, Regina Clementi, Elena Velkoska, John Feaster, C. Michael Gibson
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 9 (2024)
Externí odkaz:
https://doaj.org/article/d00adc5ec7994cd5a0831b5d186ae041
Autor:
Bo Zheng, Shinya Goto, Regina Clementi, John Feaster, Danielle Duffy, Penelope Dalitz, Jolanta Airey, Serge Korjian, Michael A. Tortorici, John Roberts, C. Michael Gibson
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 10, Pp 2331-2341 (2022)
Abstract CSL112 (apolipoprotein A‐I [apoA‐I, human]) is a novel drug in development to reduce the risk of recurrent cardiovascular events following acute myocardial infarction by increasing cholesterol efflux capacity (CEC). This phase I study ai
Externí odkaz:
https://doaj.org/article/e76816c4e21d4e1e8d8193c5446611ff
Autor:
Shinya Goto, Regina Clementi, John Feaster, Danielle Duffy, Bo Zheng, Penelope Dalitz, John Roberts, C. Michael Gibson, Serge Korjian
Publikováno v:
Journal of Clinical Lipidology. 16:e54-e55
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f7c2595eaf345b99cfb82b4df3c36ed
https://doi.org/10.1016/j.jacl.2022.05.035
https://doi.org/10.1016/j.jacl.2022.05.035
Autor:
Bo Zheng, Shinya Goto, Regina Clementi, John Feaster, Danielle Duffy, Penelope Dalitz, Jolanta Airey, John Roberts, Serge Korjian, Michael C. Gibson
Publikováno v:
Journal of the American College of Cardiology. 79:1026
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1701d4467de97dac259c91141b2e122d
https://doi.org/10.1016/s0735-1097(22)02017-4
https://doi.org/10.1016/s0735-1097(22)02017-4
Autor:
John P. Roberts, Penelope Dalitz, Danielle Duffy, Bo Zheng, Regina Clementi, Michael A. Tortorici, John Feaster, Jolanta Airey
Publikováno v:
Journal of the American College of Cardiology. 77:131
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a698d87d24d13b69e93513d1a22c8175
https://doi.org/10.1016/s0735-1097(21)01490-x
https://doi.org/10.1016/s0735-1097(21)01490-x
Autor:
Alison R. Moliterno, John Mascarenhas, Elizabeth O. Hexner, Ron Hoffman, Selina M. Luger, Martin Carroll, Regina Clementi, Gail J. Roboz, Debra M. Bensen-Kennedy
Publikováno v:
British Journal of Haematology. 164:83-93
JAK2-V617F is central to the pathogenesis of myeloproliferative neoplasms. We examined whether lestaurtinib decreased JAK2-V617F allele burden and evaluated its clinical benefits and tolerability in patients with polycythaemia vera (PV) and essential
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f22ef62d97c9d1e1e7bf358186b4b7c
https://doi.org/10.1111/bjh.12607
https://doi.org/10.1111/bjh.12607
Autor:
Mark Hertzberg, Kathryn S. Kolibaba, Mihaela C. Munteanu, David Simpson, Doreen M. Hallman, Ian W. Flinn, Ling Chen, Michael Craig, Samar Issa, Tim E. Hawkins, Regina Clementi, Yiu Lam Kwan, Brad S. Kahl, David MacDonald, Peter Wood, Richard van der Jagt, John M. Burke
Publikováno v:
Blood. 123(19)
This randomized, noninferiority (NI), global, phase 3 study evaluated the efficacy and safety of bendamustine plus rituximab (BR) vs a standard rituximab-chemotherapy regimen (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15c62b124b7e7ebdf084c0ead5d0fe83
https://pubmed.ncbi.nlm.nih.gov/31735051
https://pubmed.ncbi.nlm.nih.gov/31735051
Autor:
Regina Clementi, David Simpson, Ian W. Flinn, Michael Craig, Kathryn S. Kolibaba, Mihaela C. Munteanu, Samar Issa, Richard van der Jagt, Mark Hertzberg, Tim E. Hawkins, Ling Chen, Yiu-Lam Kwan, Doreen M. Hallman, Brad S. Kahl, David MacDonald, Peter Wood, John M. Burke
Publikováno v:
Journal of Clinical Oncology. 31:8537-8537
8537 Background: BR was previously reported to be statistically noninferior to R-CVP/R-CHOP for complete response rate in the treatment of patients with indolent NHL or MCL. Evaluation of time-to-event outcomes is immature. This subanalysis reports r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da154b08f899fb03bde08cce8c15268c
https://doi.org/10.1200/jco.2013.31.15_suppl.8537
https://doi.org/10.1200/jco.2013.31.15_suppl.8537
Autor:
Richard van der Jagt, Michael Craig, Yiu-Lam Kwan, Ian W. Flinn, Peter Wood, Samar Issa, David MacDonald, Brad S. Kahl, Tim E. Hawkins, David Simpson, Mark Hertzberg, Regina Clementi, Ling Chen, Kathryn S. Kolibaba, Mihaela C. Munteanu, John M. Burke
Publikováno v:
Blood. 120:902-902
Abstract 902 Background Bendamustine (B) is an active agent for relapsed and refractory indolent NHL, both as monotherapy and combined with rituximab (R), results recently updated by the StiL study group. This study compared efficacy and safety of BR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::01f8d99b73605c97eadcb63a6730af10
https://doi.org/10.1182/blood.v120.21.902.902
https://doi.org/10.1182/blood.v120.21.902.902
Autor:
John M. Burke, Ian W. Flinn, Yiu-Lam Kwan, Richard E. White, Ling Chen, David MacDonald, David Simpson, Samar Issa, Tim E. Hawkins, Michael Craig, Peter Wood, Brad S. Kahl, Richard van der Jagt, Kathryn S. Kolibaba, Mihaela C. Munteanu, Regina Clementi, Mark Hertzberg
Publikováno v:
Blood. 120:155-155
Abstract 155 Background Bendamustine is a unique alkylating agent, active as monotherapy and in combination with rituximab for relapsed and refractory indolent non-Hodgkin's lymphoma (NHL). This study compared efficacy and safety of bendamustine-ritu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::124d4fe553f7209740a4ddc97f82da6b
https://doi.org/10.1182/blood.v120.21.155.155
https://doi.org/10.1182/blood.v120.21.155.155